Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.62 |
| ▸ | ITK | Q08881 | 8/20 | 0.62 |
| ▸ | BTK | Q06187 | 6/20 | 0.61 |
| ▸ | BMX | P51813 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769233 | 0.90 | EGFR (0.75) | EGFRITKBTK | |
| SCHEMBL14771996 | 0.89 | BTK (0.72) | EGFRITKBTKCNR2 | |
| SCHEMBL14769165 | 0.87 | BTK (0.66) | EGFRITKBTKBMXCNR2 | |
| SCHEMBL14769180 | 0.86 | CNR2 (0.55) | EGFRITKBTKCNR2 | |
| SCHEMBL13498133 | 0.86 | EGFR (0.82) | EGFRITKBTK | |
| SCHEMBL14769135 | 0.86 | CNR2 (0.53) | EGFRITKBTKCNR2 | |
| SCHEMBL12519517 | 0.84 | ITK (0.84) | EGFRITKBTK | |
| SCHEMBL18165631 | 0.80 | EGFR (0.76) | EGFRITKBTK | |
| SCHEMBL12519528 | 0.78 | ITK (0.79) | EGFRITKBTK | |
| SCHEMBL21109653 | 0.78 | ITK (0.84) | EGFRITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710222-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ITK 2697/4885BTK 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.